¿¼²©±¨°à ¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ÿÈÕÇ©µ½
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æרҵ£º sKIWr{D  
aNb=gjLpt  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Mt)~:V+:  
#(3w6 l2  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) rb%P30qc4  
 X>OO4SV  
1. ICAM-1 dA> t  
!q~s-~d^  
2. interleukin 12(IL-12) =]E(iR_&  
g[Ah> 5  
3. tumor infiltrating lymphocyte %@q52ZQ  
aWek<Y~+  
4. TCR/CD3 complex yCkfAx8 ]  
!>b>"\b  
5. hematopoietin receptor family QU16X  
leyhiL<  
6. individual idiotype(IdI) }MY7<sMDOy  
z=<T[Uy  
7. integrin CyO2Z  
3;~1rw=$<  
8. colony-stimulatory factor (CSF) `x$d8(1J`#  
X!&DKE  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© !y$H r[v  
q,V JpqQ  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? Tn2Z{.q$  
q7mqzMDk  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ /A}3kTp  
OGg9e  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ^DXERt&3  
7!w@u6Q  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØϵ¡£ { ,.1KtrSN  
fL ng[&  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) 85$MHod}[,  
#rMMOu9r2  
1. ÊÔÊö¸ÉÈÅËصķÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌص㡣Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËؼì²âµÄ·½·¨ºÍÔ­Àí¡£ :Gqyj_|<  
>T;"bc b  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ä¿Ç°¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æרҵ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) [' R2$z  
>WE3$Q>bi  
3. immunoglobulin superfamily (IgSF) G% S=K2 v  
LdI)  
4. selectin w_@N T}  
4Cke(G  
5. anti-idiotypic antibody (¦ÁId) 'Kxs>/y3  
}|H]>U&  
6. major histocompatibility complex(MHC) v3[Z ]+ ]  
M|?qSFv:  
7. immunotolerance 8U0y86q>)E  
d~C YZ  
8. biological reponse modifier(BRM) gSEj/?  
f"xi7vJv!f  
9. immune reponse gene (Ir gene) YKf,vHau  
C>$5<bx  
10. reshaped antibody (or reconstituted antibody) _ot4HmD  
LT!B]y  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© v~q2D"   
;nji<  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ -Vn9YeH+  
g Z   
2. ϸ°û¶¾ÐÔTÁÜ°Íϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? @Rj&9/\L  
dl'pl  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ vi 4 u `  
!Y!Cv %  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? ylLQKdcL  
'I($IM  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ uaNJTob  
+Q If7=  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? l?NRQTG  
/ S$p_7N  
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ 699z@>$}  
= PcmJG]  
¹©Ïû»¯ÄÚ¿ÆרҵÊÔÌ⣺ rhMsZ={M  
Ym(^ i h  
1. Ä¿Ç°ÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨?  g[@K d  
4wX{N   
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ XPd>DH(Yc  
eU1= :n&&\  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æרҵ: ~7Kqc\/H&I  
=#&K\  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: &}nU#)IX  
}.3F|H  
ÃâÒßѧ '(5 &Sj/C  
A5!j rSyv  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© HD IB GG~  
[V  T&  
1. CD8 im>Sxu@  
J|sX {/WT  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) XrYMv WT  
M E[Wg\  
3. immunoglobulin fold(Ig fold) ZO2u[HSO>  
v!E0/ gD  
4. cadherin (Ca-dependent cell adhesion moleculers) @b=tjQO_  
(?J6vK}S  
5. idiotype-anti-idiotypic antibody immune network theory x1Q}B   
K $\az%NE  
6. HLA class II antigen :4}?%3&;  
?1x BhKq  
7. complementarity-determining region (CDR) F@kOj*5,[  
o{4ya jt  
8. perforin(or pore-forming protein ,PFP) ,ZJI]Q=!  
)F0 _V 4  
9. high affinity IL-2 receptor  @zEEX9U  
z_*]joL  
10. artificial active immunization g:q+.6va"  
RsIEY5Q  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© q =b.!AZy  
;wbQTp2  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ&jl'1mZ  
HPCzh  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 oB-&ma[ZS  
Xl#vVyO  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ %/oOM\} ++  
 Fla[YWS  
4. ÊԱȽÏT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃ濹ԭ¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ N;F1Z-9  
+%>s\W+?]  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐÑ¡Ò»Ìâ,3¡¢4ÌâÖÐÑ¡Ò»Ìâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ä¿Ç°¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£  &{7n  
=3{h9  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? Y` LZ/Tgk  
%+w>`k3(N  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ?f1%)]>   
j^1T3 +  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ ;} gvBI2e  
'P)xY-15  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ @?aNvWeavH  
8!TbJVR  
ѧ¿Æרҵ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ #v:<\-MjN  
29Kuq;6  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 4.,e3  
1UJ(._0hR  
1. immunoglobulin gene rearrangement ( ]AErz+  
O!d^v9hM,  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) tW|B\p}  
~`#.ZMO  
3. flow cytometry(FCM) eoR@5OA&  
(*/P~$xIj  
4. carrier effect 9$~D4T  
1;fs`k0p  
5. positive selection of T lymphocytes in thymus 5WO!u:!'  
_( w4\]  
6. mouse TH1(Th1) and TH2(Th2) subsets ZZ!d:1'7  
9=rYzA?)+  
7. perforin (pore-forming protein ,PFP) F ` J(+  
E-*udQ  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) b=F"  
`*KS` z?  
9. SH-2(src-homology region 2) bLCrh(<  
 *X*D, VY  
10. Ab2¦Â (internal image) To}L%)   
PgB=<#9  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© MG8-1M  
@`%.\_  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? }=?r`J+Ev;  
HZ[&ZNTa  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? @*is]d+Ya  
QdUl-(  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠt^8# ~o!%  
~>>o'H6  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ g|)e3q{M  
Qyt6+xL  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠu+(e, t  
at7/KuY!~  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) bTO$B2eh|  
fkRb;aIl  
ÃâÒßѧרҵ£º &bBp`h  
-d_FB?X  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ eC[g"Ef  
168 U-<  
2. ÊԱȽÏÈËT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? oJ6 d:  
"Hg n2o.;5  
´«È¾²¡Ñ§×¨Òµ£º Bfi9%:eG  
~+CNED0z+  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦ÄÜ¿É·¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ -7=pb#y  
+Tq _n@  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØϵ¡£ #Sn&Wo  
^$?8! WE  
Ïû»¯×¨Òµ£º QXXc Jc~  
FAPgXmFzx  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ >x!N @G  
61jDI^:  
2.¼òÊöճĤÏà¹ØÁÜ°ÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌص㡣·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? m#8}!u&  
Bm~>w`1wK  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ >!bYuVHA  
/Zm@.%.  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© YRC`2)_'  
3P #1fI(c  
1. Fas(CD95)/FasL Dt r'X@U  
ve  K  
2. common chain of cytokine receptor *}mtVa_|  
@XmMD6{<  
3 . TCR/CD3 complex 7[u&%  
sjaG%f&h  
4. negaive selection of thymocytes yM\ 1n  
\O Y2|  
5. artificial active immune xmVK{Q YT$  
8|J%IE  
6. anti-idiotypic -Tz9J4xU&  
E"w7/k#3}C  
7. IgSF aZBaIl6I  
$"_D"/*  
8. Integrin pl7!O9bo  
%ecg19~L/}  
9. chemokine R0m}I5Frs  
>+$1 p_  
10. B7/CD28 ueqR@i  
c\RDa|B,  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© 5gEUE{S  
,:;_j<g`e  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ v"bOv"!al  
^M,Q<HL  
2. ±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌص㡣 Yoaz|7LS  
85H8`YwPh  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ lYJ]W[!  
<M 7WWtmx  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆʵÑé·½°¸¿Ë¡´Ë»ùÒò¡£ ^WUF3Q**OU  
-M(:z  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ J6f;dF^  
rb,&i1  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ b$M? _<G  
4} =]QQoE  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© [81k4kU  
-i 6<kF-W  
1. B7/CD28 RAxA H   
Y&+<'FA  
2. Th1 subset `Y$LXF~,Om  
9ft7  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© E8)C_[QJ`  
FIW*N r  
4. antibody affinity maturation Ag}>gbz~G  
^i@tOtS  
5. AP-1 BQ".$(c q  
m]&d TZV  
6. single chain variable fragment£¨ScFv£© {?#g*QF|^  
qzmY]N+w|  
7. NK cell receptor t7R;RF  
@8DA  
8. Zinkernagel-Doherty phenomenon m&o&XVC  
szWh#O5=  
9. Ig fold +tlTH K  
I~#'76L[  
10. CD40/CD40L [x,_0-_  
nq A> }A  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© qhiQ!fMQ  
{3`9A7bG  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØϵ¡£ +&Sf$t 1  
!^B`7  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ 6 {5*9!v63  
nj #Ab  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹Øϵ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ 2h u;N  
k\1q Jr  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ +9,"ne1'e  
S9-K  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁÜ°Íϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£  |o=eS&)  
h6la+l?x  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ ^;Ap-2Ww  
O_(/uLH  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æרҵ£©¡£ p@>_1A}qh_  
#ZF|5 r +  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© :+m|KC(Z  
}.MJVB3  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© ~kw[Aw3?D\  
LW0't} z  
1.Co-stimulators (or co-stimulating molecules) A2$:p$[  
d; V  
2.NK-kB YD7i6A  
`R=8=6Z+$q  
3.Immunoglobulin superfamily  2o?!m2W  
%/-Z1Nv*#  
4.antigen-presenting cell (APC) }4  5|  
r4A%`sk @  
5.death domain * t{A=Wk  
7AHEzJh"  
6.CCR and CXCR asmMl9)(`  
T&X*[ kP  
7.Lectin (or mitogen) !+=jD3HTJ  
a[[u>oHyd  
8.Clusters of differentiation, CD) f-tjMa /_  
h 5t,5e}  
9.B7 family )pW(Cp  
8'@pX<  
10.Cytotoxic T lymphocyte, CTL) -U'6fx) +  
k 2_ "  
11.IL-15 and IL-15 receptor (IL-15R) q --NLm@;  
WojZ[j>  
12.MHC restriction P`cEu6:  
.~4%TsBaY  
13.Affinity-chromatography yf2U-s  
|j#x}8 [(  
14.Cyctosprin A, CsA ;vc$;54K  
? D2:'gg  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) 90Jxn'>^  
(iIJ[{[H4)  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© c{ +Y $  
V+W,# 5  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 S/"-x{Gc2v  
7ZI!$J|  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ w(]Q `  
&D\~-fOGb  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌص㡣 q UY;CEf  
vHCz_ FV  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© J'sVT{@GS  
]HgAI$aA,  
ÃâÒßѧרҵ£º vClD)Ar  
(@vu/yN  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ '3 xvQFg  
N5Eb.a9S  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ -4m UGh1dy  
l 'fUa  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ H5j~<@STC  
6=3}gd5  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) g<-x"$(C&  
B5hk]= Ud  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) P PZxH}J.  
d}GO(  
1. ADCC(antibody dependent cell-mediated cytotoxicity) 2VyLt=mdh  
H,9e<x#own  
2. »·æß¾úËØ(cyclosporin) $ &M"Ji  
d nWh}!  
3. KIR(killer cell inhibitory receptor) gm B?L0UV  
~Aq;g$IJZ  
4. HLDA(human leucocyte differentiation antigen) e*;-vS9H  
:(VD<"X  
5. Interleukin 18(IL-18) @[D-2s  
a]|P rjPI  
6. ÕûºÏËØ(integrin) `{s:lf  
;>{B K,  
7. Fas/FasL dU+28  
r5t C  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) 8q{ %n   
Fr?o 4E6h  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) y)X1!3~(  
,.6Hh'^65^  
10. Th1/Th2 .e%PK  
 *[t@j*al  
11. »ùÒòÒßÃç(DNAÒßÃç) 'kPc `) \  
\^or l9  
12. chemokines and chemokine receptor l'n"iQ!G  
/DA'p[,  
13. ÃâÒßÄÍÊÜ Ll\y2oJ  
[GJ_]w^}j  
14. ¹²´Ì¼¤·Ö×Ó yyb8l l?@a  
xhLVLXZ9  
15. ËÀÍö½á¹¹Óò(death domain) ?a+>%uWt  
$e1==@ R  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) 42kr&UY&  
gZF-zhnC  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉË°Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? 8%q:lI  
sr1`/  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»Æƶø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ:^]rjy/|+  
2&7:JM~#  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î kBg,U8|S  
#e:cB'f  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ KfD=3h=  
UPQ?vh2F2  
£¨3£©1984Ä꣺ÁÜ°Íϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå hF|N81T  
HE#IJB6BS?  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄЩÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ 7 06-QE^  
<WhdQKFf-  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) .&fG_(6|  
%" kF i  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ IJ >qs8  
NH+?7rf8  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ x{y}pH"H  
*9Eep~ 6  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆһϵͳʵÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃÇ°¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÍøÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»